Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 

 Table of Contents      
Year : 2013  |  Volume : 34  |  Issue : 4  |  Page : 330-332  

Cisplatin induced paroxysmal supraventricular tachycardia

1 Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
2 Department of Cardiology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India

Date of Web Publication18-Jan-2014

Correspondence Address:
Waseem Raja
Walk In. 15 Lambert Lane, Residency Road Lalchowk, Srinagar - 190 011, Jammu and Kashmir
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-5851.125262

Rights and Permissions

Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of platinum-containing anti-cancer drugs that act by binding to and causing cross-linking of deoxyribonucleic acid, which ultimately triggers apoptosis. Cisplatin has a broad-spectrum antineoplastic activity against various types of human tumors. Unfortunately, the optimal usefulness of Cisplatin is limited secondary to its dose related toxicity especially nephrotoxicity. Cisplatin chemotherapy is also associated with cardiotoxic effects that may range from silent arrhythmias to heart failure and even sudden cardiac death. These effects are more pronounced when cisplatin is combined with other cardiotoxic drugs. Here, we report a case of patient of cancer lung who developed paroxysmal supraventricular tachycardia following administration of Cisplatin. A brief review of the literature follows.

Keywords: Cisplatin, lung cancer, paroxysmal supraventricular tachycardia

How to cite this article:
Raja W, Mir M H, Dar I, Banday MA, Ahmad I. Cisplatin induced paroxysmal supraventricular tachycardia. Indian J Med Paediatr Oncol 2013;34:330-2

How to cite this URL:
Raja W, Mir M H, Dar I, Banday MA, Ahmad I. Cisplatin induced paroxysmal supraventricular tachycardia. Indian J Med Paediatr Oncol [serial online] 2013 [cited 2020 May 30];34:330-2. Available from: http://www.ijmpo.org/text.asp?2013/34/4/330/125262

  Introduction Top

Chemotherapy may induce entire spectrum of cardiac pathology. Cisplatin (CDDP) is a widely used chemotherapeutic agent and its use is limited by its wide range of toxicities, most common being renal and neurotoxicity. Cardiotoxicity of cisplatin is less common and may range from silent and symptomatic arrhythmias to cardiomyopathy and sudden death. Paroxysmal supraventricular tachycardia (PSVT) due to cisplatin is rare mentioned in only few case reports. We report a patient with no prior history of cardiac ailment who developed PSVT on administration of cisplatin that aborted once cisplatin was stopped.

  Case Report Top

Our patient was a 55-year-old male who had been recently diagnosed as having small cell carcinoma of the right lung. Patient was normotensive and had no underlying cardiac illness. Baseline electrocardiogram (ECG) and Echocardiography were normal as were other parameters [Figure 1]a. He was planned for cisplatin based chemotherapy Cisplatin (62 mg D 1, D2 + Etoposide 165 mg D 1, D2, D3). Patient received first cycle of chemotherapy uneventfully. During the second cycle while on cisplatin infusion, patient complained of palpitations. An ECG was performed that revealed PSVT [Figure 1]b. Cisplatin infusion was stopped and the patient was given diltiazem 15 mg intravenous. Meanwhile, blood samples were collected for serum Na + , K + , Ca 2+ and Mg 2+ , which were reported as normal. Echocardiography and electrophysiological studies were carried out later, which were normal. Besides, subsequent ECGs were also normal [Figure 1]c. Patient received tab bisoprolol 5 mg prior to each cycle and didn't develop any arrhythmia in subsequent cycles.
Figure 1:

Click here to view

  Discussion Top

Cisplatin is a potent chemotherapeutic drug that is used in a broad range of cancers. [1] It was first described by M. Peyrone in 1845 and was known for a long time as Peyrone's salt. [2] Cisplatin was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration on December 19, 1978. The use of Cisplatin is limited by its toxicity that includes nephrotoxicity, neurotoxicity, gastrointestinal side effects, ototoxicity and others. Cardiotoxicity due to cisplatin includes electrocardiographic changes, arrhythmias, myocarditis, cardiomyopathy and congestive heart failure. Entire spectrum of arrhythmia, including supraventricular tachycardia, bradycardia and block in any degree may be observed during or shortly after cisplatin administration, some of them being clinically important and may cause death. [3] Cardiac toxicity of Cisplatin can be either due to a direct toxic action on cardiac myocytes or due to reactive oxygen species (ROS) production and the subsequent induction of oxidative stress and switch to a prothrombotic condition. [4],[5] However, it is known that cisplatin frequently induces alterations in the electrolyte balance, in particular intracellular and extracellular potassium and magnesium concentrations. Such electrolyte imbalances are likely to play a significant role in the pathogenesis of cisplatin-induced arrhythmias. [6] Ozlem et al. studied the prevalence of silent arrhythmia in patients receiving cisplatin-based chemotherapy. They found cisplatin-related acute arrhythmia in any degree in as many as 66.7%, all which were silent. They concluded that the mechanism of cisplatin induced cardiac arrhythmias seems to be independent of changes in the serum electrolyte levels and may be due to the direct effect of the drug on cardiac sodium channels leading to an increase in QT dispersion or any other mechanism, which may cause inhomogeneity of ventricular recovery. [7] In addition to arrhythmias, cisplatin also produces cardiac dysfunction predominantly diastolic, whereas the rate of systolic dysfunction remains low. Several agents have been investigated for the potential role in ameliorating the cardiotoxicity of cisplatin. [8],[9] Resveratrol, acetyl-l-carnitine, DL-α-lipoic acid and silymarin have been found to protect cardiomyocytes from cisplatin-induced cardiotoxicity.

Our patient didn't have a history of any cardiac ailment and developed PSVT during cisplatin infusion that reverted back once cisplatin infusion was stopped. Electrolytes were normal. His cardiac evaluation including echocardiography and electrophysiological studies were normal. Thus, it was concluded that PSVT in this patient was secondary to cisplatin induced cardiotoxicity. Patient received subsequent cycles of chemotherapy without any problems.

  Conclusion Top

Cisplatin is a useful antineoplastic drug with activity against a broad range of cancers. However, toxicity due to cisplatin is quite common and may result in stoppage of the drug. Cardiotoxicity of cisplatin can be symptomatic or symptomatic. Several antioxidants are being evaluated for a protective role in preventing cisplatin induced cardio toxicity.

  References Top

1.Peyrone M. On the action of ammonia on platinous. Ann Pharm Chem 1844;51:1-29.  Back to cited text no. 1
2.Carpenter DP. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press.  Back to cited text no. 2
3.Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P, et al. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: Role of the antioxidants in chemoprevention. Rejuvenation Res 2011;14:293-308.  Back to cited text no. 3
4.Zumkley H, Bertram HP, Preusser P, Kellinghaus H, Straub C, Vetter H. Renal excretion of magnesium and trace elements during cisplatin treatment. Clin Nephrol 1982;17:254-7.  Back to cited text no. 4
5.Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929-31.  Back to cited text no. 5
6.Yavas Ö, Aytemir K, Celik Ý. The prevalence of silent arrhythmia in patients receiving cisplatin-based chemotherapy. Turk J Cancer 2008;38:1.  Back to cited text no. 6
7.Altena R, Hummel YM, Nuver J, Smit AJ, Lefrandt JD, de Boer RA, et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011;22:2286-93.  Back to cited text no. 7
8.Wang J, He D, Zhang Q, Han Y, Jin S, Qi F. Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009;24:675-80.  Back to cited text no. 8
9.El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011;650:335-41.  Back to cited text no. 9


  [Figure 1]

This article has been cited by
1 Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management
Michael E. Layoun,Chanaka D. Wickramasinghe,Maria V. Peralta,Eric H. Yang
Current Oncology Reports. 2016; 18(6)
[Pubmed] | [DOI]
2 Cisplatin
Reactions Weekly. 2014; 1491(1): 15
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
  Case Report
   Article Figures

 Article Access Statistics
    PDF Downloaded287    
    Comments [Add]    
    Cited by others 2    

Recommend this journal